KR890011603A - 항암 결합체 - Google Patents

항암 결합체 Download PDF

Info

Publication number
KR890011603A
KR890011603A KR1019890000634A KR890000634A KR890011603A KR 890011603 A KR890011603 A KR 890011603A KR 1019890000634 A KR1019890000634 A KR 1019890000634A KR 890000634 A KR890000634 A KR 890000634A KR 890011603 A KR890011603 A KR 890011603A
Authority
KR
South Korea
Prior art keywords
anticancer
conjugate according
aldohexopyranose
ring
carrier
Prior art date
Application number
KR1019890000634A
Other languages
English (en)
Inventor
고지 무네찌까
야수오 우에다
아끼히또 기꾸까와
다까시 나까에
고우이찌 야마노우찌
Original Assignee
수야마 다다가즈
그린 크로스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수야마 다다가즈, 그린 크로스 코포레이션 filed Critical 수야마 다다가즈
Publication of KR890011603A publication Critical patent/KR890011603A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

내용 없음

Description

항암 결합체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 알도헥소피라노즈 환-분해 텍스트란이 텍스트란을 보호하는 아미노산의 카복실 그룹 및 담체상의 아미노 그룹을 통하여 담체와 결합되어 있고 상기 엑스트란의 상의 알데히드 그룹 및 항암 물질상의 아미노 그룹을 통하여 항암물질과 결합되어 있음을 특징으로 하는, 알도헥소피라노즈 환-분해 텍스트란을 통해 담체에 커플링되어있는 항암 물질을 함유하는 항암 결합체.
  2. 제1항에 있어서, 알도헥소피라노즈 환-분해 텍스트란 상의 알데히드 그룹 5내지 70%가 보호된 항암 결합체.
  3. 제1항에 있어서, 항암 물질이 미토마이신 C, 아드리아마이신 또는 다우노마이신인 항암 결합체.
  4. 제1항에 있어서, 담체가 감마-글로블린, 암 특이적 폴리클로날 또는 모노클로날 항체, 피브로넥틴, 트랜스페린 및 피브리노겐을 이루어진 그룹중에서 선택되는 적어도 하나의 성분인 항암 결합체.
  5. 제1항에 있어서, 상기 분해 덱스트란의 분자량이 1,000내지 100,000인 항암 결합체.
  6. 제5항에 있어서, 상기 분해 덱스트란의 분자량이 10,000내지 70,000인 항암 결합체.
  7. 제2항에 있어서, 알도헥소피라노즈 환-분해 덱스트란 상의 알데히드 그룹 10내지 50%가 보호된 항암 결합체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000634A 1988-01-22 1989-01-21 항암 결합체 KR890011603A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-13089 1988-01-22
JP63013089A JPH01190636A (ja) 1988-01-22 1988-01-22 制癌作用物質複合体

Publications (1)

Publication Number Publication Date
KR890011603A true KR890011603A (ko) 1989-08-21

Family

ID=11823434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000634A KR890011603A (ko) 1988-01-22 1989-01-21 항암 결합체

Country Status (3)

Country Link
EP (1) EP0325270A3 (ko)
JP (1) JPH01190636A (ko)
KR (1) KR890011603A (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040045794A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 아드리아마이신을포함하는 복합 항암제
KR20040045795A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
ES2117664T3 (es) * 1991-02-21 1998-08-16 Drug Delivery System Inst Ltd Carboximetilmanoglucanos y derivados de los mismos.
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60323936D1 (de) 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
WO2004009774A2 (en) * 2002-07-19 2004-01-29 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
CA2492803C (en) 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7790150B2 (en) 2003-09-05 2010-09-07 The General Hospital Corporation Dual phase drug release system
EP1926498A2 (en) * 2005-09-22 2008-06-04 Hadasit Medical Research Services And Development Company Ltd. Dextran and arabinogalactan conjugates of therapeutically active compounds
US8329870B2 (en) 2007-01-04 2012-12-11 Hepacore Ltd. Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
KR100971271B1 (ko) * 2008-04-28 2010-07-20 한양대학교 산학협력단 헤파린이 결합된 피브린젤, 그 제조방법 및 키트
PA8853201A1 (es) 2008-12-10 2010-07-27 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
PL221351B1 (pl) * 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6089433A (ja) * 1983-10-21 1985-05-20 Green Cross Corp:The 制癌作用物質複合体の製造法
JPS60226819A (ja) * 1984-04-25 1985-11-12 Green Cross Corp:The フイブロネクチン複合体
JPS62283101A (ja) * 1986-05-30 1987-12-09 Green Cross Corp:The 制癌作用物質複合体の製造方法
JPS63264427A (ja) * 1986-12-17 1988-11-01 Green Cross Corp:The 制癌作用物質複合体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040045794A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 아드리아마이신을포함하는 복합 항암제
KR20040045795A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

Also Published As

Publication number Publication date
EP0325270A3 (en) 1991-01-30
EP0325270A2 (en) 1989-07-26
JPH01190636A (ja) 1989-07-31

Similar Documents

Publication Publication Date Title
KR890011603A (ko) 항암 결합체
ATE121787T1 (de) Neuer monoklonaler antikörper gegen menschliches karzinom.
KR930002382A (ko) 배향된 광중합체 및 이의 제조방법
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DE69419160T2 (de) Dichtungen hergestellt aus homogenen, linearen olefinpolymeren
KR890007754A (ko) 항체류의 안정화
ATE120233T1 (de) Monoklonale antikörper, b-spezifisch für apolipoprotein, die von zwei hybridomen erzeugt werden.
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3683322D1 (de) Sofort vernetzbare zusammensetzung.
KR860006542A (ko) 안정화된 효소결합체 조성물
KR910018460A (ko) 열가소성 수지 조성물
IT1118600B (it) Percedimento di incorporamento di immagini in sorronti in resina sintetica particolarmente per fopocraete da applicare su lapidi mortuarie e relativo prodotto ottenuto
KR890009386A (ko) 백금화합물 동결건조제제
KR900009374A (ko) 캐리어 팔레트
KR940021630A (ko) 투습방지용 폴리에틸렌 필름
KR910007178A (ko) 전파 흡수체
KR940702479A (ko) 칼콘 골격을 갖는 화합물의 복합체
FR2674216B1 (fr) Boite d'emballage, destinee notamment au conditionnement de friandises.
KR910007943A (ko) N-디클로로포스포릴트리클로로포스파젠 및 그의 중축합 생성물의 불순물의 해로운 영향 보완 방법.
MX9700163A (es) Composiciones de revestimiento durable.
KR910008061A (ko) 열가소성 수지조성물
KR900014598A (ko) 변형된 pe_40의 제조
KR910007506A (ko) 세포 보호제
KR910007180A (ko) 전파 흡수체
KR910020092A (ko) 자동차 범퍼용 폴리프로필렌 수지 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid